🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Accendra Health, Inc. ACH R2K

Healthcare · Medical Distribution · United States
https://www.accendrahealth.com
Company Profile ↓
$3.63
-54.45% 1Y
Mkt Cap$278.00M
P/E-2.65
P/B-0.55
52W High$8.24
52W Low$1.91
Book Value$-6.07
EPS (TTM)$-1.37

Company Overview

Accendra Health, Inc., together with its subsidiaries, operates as a healthcare solutions company in the United States. It offers a range of products and services for in-home care and delivery for diabetes treatment; home respiratory therapy, including home oxygen and non-invasive ventilation services; obstructive sleep apnea treatment, such as continuous positive airway pressure and bi-level positive airway pressure devices, and patient support services. The company also supplies other home medical equipment, patient care product lines including ostomy, wound care and negative pressure wound therapy, urology, incontinence, and other products and services. It serves patients and home health agencies. The company was formerly known as Owens & Minor, Inc. and changed its name to Accendra Health, Inc. in December 2025. Accendra Health, Inc. was founded in 1882 and is based in Glen Allen, Virginia.

Why Investors Should Care

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Dec 2025 Revenue of $2.76B (+3.1% YoY); net profit $-1.10B.
  • Trailing 12 Months Year-on-year growth — revenue -6.8%.
  • 5-Year Trend Long-term compounding — revenue CAGR -34.8%, profit CAGR -1672.0%.

Growth & Price Performance

Compounded Sales Growth

5 Years:-34.78%
1 Year:-6.80%

Compounded Profit Growth

5 Years:-1,672.00%
1 Year:-

Stock Price Performance

1 Year:-54.45%
6 Months:+35.45%
3 Months:+15.24%
1 Month:+9.01%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 27% of range
$1.91 $8.24
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)61.27 · Neutral
Price Performance
1M+9.01%
3M+15.24%
6M+35.45%
1Y-54.45%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Revenue declined at -34.8% CAGR over 5 years.
  • Earnings shrank at -1672.0% CAGR over 5 years.
  • Trading 56.0% below its 52-week high.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-2.65
Industry PE
25.88
Forward P/E
5.28
PEG Ratio
0.70
Book Value
$-6.07
Price to Book
-0.55
P/S
0.09
EV/EBITDA
6.45
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
-34.78%
Profit 5Y
-1,672.00%
Revenue (YoY)
-6.80%
Earnings (YoY)
-

Profitability & Returns

ROCE
0.35%
ROE
-
ROA
1.55%
Profit Margin
-39.84%
Op Margin
-1.02%
Gross Margin
45.95%
EPS (Latest Qtr)
$-0.08
EPS (TTM)
$-1.37

Balance Sheet & Liquidity

Debt/Equity
-
Quick Ratio
0.37
Current Ratio
0.49
Debt
$2.17B
Total Assets
$2.42B
Current Assets
$588.50M
Working Capital
$-399.20M

Ownership

Promoter Holding
-
Chg in Prom Hold
-
FII / Inst Holding
-
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
$278.00M
Total Revenue (TTM)
$2.72B
EBITDA
$323.73M
Free Cash Flow
$650.28M
Operating Cash Flow
$-116.80M
Shares Outstanding
76.58M
Gross Margin
45.95%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 ACH Accendra Health, Inc. R2K 3.63 -2.65 $278.00M 0.00% 0.35% - -34.78% -1,672.00%
2 LLY Eli Lilly and Company SPX 1,156.63 41.13 $1.03T 0.60% - 107.46% 7.20% 11.41%
3 JNJ Johnson & Johnson SPX 247.02 28.66 $594.63B 2.23% 14.88% 26.42% 2.43% 4.76%
4 ABBV AbbVie Inc. SPX 244.11 119.08 $431.29B 3.04% 10.47% -129.24% 1.75% -29.06%
5 UNH UnitedHealth Group Incorporated SPX 418.52 31.54 $380.08B 2.18% 9.74% 12.18% 10.40% 5.43%
6 MRK Merck & Co., Inc. SPX 123.61 34.82 $305.29B 2.82% - 18.94% 5.64% 10.01%
7 AZN AstraZeneca PLC NDX 168.37 26.10 $261.12B 1.87% 15.97% 23.48% 9.82% 45.96%
8 TMO Thermo Fisher Scientific Inc. SPX 535.29 29.40 $198.93B 0.35% 8.14% 13.52% 8.81% 12.95%
9 AMGN Amgen Inc. NDXSPX 358.32 24.92 $193.39B 2.80% 18.02% 101.32% 11.77% 5.58%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Sep 2013Mar 2014Jun 2014Sep 2014Mar 2015Jun 2015Sep 2015Mar 2016Jun 2016Sep 2016Mar 2017Jun 2017Sep 2017Mar 2018Jun 2018Sep 2018Mar 2019Jun 2019Sep 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue ------------2.33B2.37B2.46B2.46B2.35B2.38B2.29B2.12B1.81B2.19B2.33B2.49B2.50B2.41B2.50B2.50B2.52B2.56B2.59B2.61B660.40M--673.88M681.92M697.26M708.97M627.78M
Cost of Revenue -----------------------------------354.64M357.31M375.07M385.71M349.75M
Gross Profit 273.33M281.19M282.27M292.48M297.60M298.34M306.35M296.64M299.42M296.27M281.18M273.53M301.94M324.69M324.99M352.57M276.62M286.52M280.62M268.56M269.41M344.34M442.75M400.07M328.84M373.45M532.50M513.28M497.31M519.43M538.50M535.53M544.15M--319.24M324.60M322.20M323.26M278.03M
Operating Expenses -----------------------------------262.37M267.85M265.84M271.50M255.23M
Operating Income 49.22M46.28M37.10M35.38M40.98M47.86M53.57M44.97M52.05M53.57M35.52M32.84M29.67M24.22M-172.05M21.36M16.60M15.90M26.11M10.76M22.20M75.55M146.69M96.88M62.88M61.06M75.08M60.25M9.81M10.84M23.84M9.70M16.92M--56.87M56.75M56.36M51.76M22.80M
EBITDA -----------------------------------61.72M18.71M89.49M49.83M77.84M
Interest Expense -----------------------------------24.21M26.01M29.03M27.93M32.35M
Pretax Income ------------------------------------5.40M-84.95M-3.63M-7.97M-16.25M
Tax Provision ------------------------------------1.59M-1.13M1.97M1.47M-9.78M
Net Income 27.97M25.48M19.88M---28.18M24.14M27.72M29.83M18.79M20.14M10.87M8.15M-182.78M-565.00K-14.10M-10.48M1.22M-11.32M-55.63M46.08M69.59M65.90M44.13M39.28M28.60M12.50M-24.42M-28.24M-6.43M-21.89M-31.91M---24.98M-869.06M-150.28M-56.33M-6.47M
Diluted EPS 0.440.410.320.110.300.390.450.390.450.480.310.33---------0.910.760.980.870.580.520.370.16-0.32-0.37-0.08-0.29-0.42---0.32-11.30-1.94-0.73-0.08

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 7.24B8.04B8.12B8.63B8.87B9.07B9.44B9.77B9.72B9.32B9.42B9.21B8.48B-9.96B2.55B2.68B2.76B
Cost of Revenue --------------8.13B1.34B1.40B1.47B
Gross Profit 741.11M814.39M807.73M857.54M924.65M1.12B1.17B1.21B1.19B1.17B1.07B1.13B1.28B-1.83B1.22B1.28B1.29B
Operating Expenses --------------1.55B1.00B1.08B1.07B
Operating Income 180.72M201.28M195.94M203.51M196.75M198.08M159.54M200.36M199.60M89.25M-352.35M73.15M204.12M-276.78M215.36M198.04M221.74M
EBITDA --------------368.45M342.40M-41.04M219.75M
Interest Expense --------------128.89M116.77M107.57M107.18M
Pretax Income --------------10.89M15.27M-329.88M-101.95M
Tax Provision ---------------11.50M6.36M20.85M729.00K
Net Income 93.33M104.66M110.58M115.20M109.00M110.88M66.50M103.41M108.79M72.79M-437.01M-62.37M29.87M-22.39M-41.30M-362.69M-1.10B
Diluted EPS 1.501.671.751.811.721.761.061.651.76---1.030.47-0.29-0.54-4.73-14.31
R&D Expense -------------12.10M12.00M13.00M13.00M-

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --1.75B1.82B1.95B2.21B2.32B2.74B2.77B2.72B3.38B3.77B3.64B3.34B-5.39B5.09B4.66B2.45B
Current Assets ---------------2.30B2.10B2.02B547.87M
Cash & Equivalents 10.39M7.89M96.14M159.21M135.94M97.89M101.91M56.77M161.02M185.49M104.52M66.31M67.03M83.06M-69.47M243.04M27.57M281.99M
Inventory ---------------1.33B1.11B67.58M74.44M
Receivables ---------------763.50M598.26M218.27M95.91M
Total Liabilities --977.91M964.52M1.03B1.24B1.30B1.74B1.78B1.76B2.36B3.26B3.18B2.62B-4.44B4.17B4.07B2.91B
Current Liabilities --700.12M694.48M732.37M925.64M990.21M966.58M1.06B1.03B1.31B1.47B1.42B1.35B-1.57B1.89B1.85B947.08M
Long Term Debt ---209.10M212.68M215.38M212.79M608.55M568.50M564.58M900.74M1.65B1.51B986.02M-2.48B1.89B1.80B1.80B
Total Debt ---------------2.72B2.32B1.93B2.12B
Total Equity 614.36M689.05M769.18M857.52M918.09M972.53M1.02B990.84M992.59M960.04M1.02B518.42M462.15M712.05M-945.60M924.17M586.36M-460.98M
Shares Outstanding ---------------76.28M76.55M77.20M76.39M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -----140.55M-3.76M270.24M187.69M56.77M115.59M166.09M339.22M-325.01M740.71M161.50M-101.79M
Investing Cash Flow ------57.08M-317.25M-36.47M-24.75M-416.64M-815.83M-51.90M80.07M--1.80B-137.25M-116.53M144.42M
Financing Cash Flow ------81.98M278.56M-124.88M-142.70M272.81M701.07M-130.20M-379.39M-1.50B-417.33M-267.60M188.08M
Capital Expenditure -17.67M-19.75M-31.22M-24.98M-9.83M-28.12M-48.42M-20.53M-20.30M-34.61M-44.87M-42.42M-50.42M--166.58M-178.53M-182.66M-201.32M
Free Cash Flow -----112.44M-52.19M249.71M167.39M22.16M70.72M123.67M288.80M-158.42M562.18M-21.17M-303.12M
Net Change in Cash --------------17.64M186.13M-222.64M230.71M
Share Buybacks ---16.12M15.00M18.88M9.93M20.00M71.03M5.00M0------10.18M
Dividends Paid 33.05M38.37M44.78M50.91M55.68M60.73M63.10M63.65M63.38M63.15M48.20M5.23M648.00K731.00K00--

Ratios (Annual)

Figures in %.

Metric Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % 10.2%10.1%9.9%9.9%10.4%12.3%12.4%12.4%12.2%12.6%11.4%12.3%15.1%-18.3%47.7%47.8%46.7%
Operating Margin % 2.5%2.5%2.4%2.4%2.2%2.2%1.7%2.1%2.1%1.0%-3.7%0.8%2.4%-2.8%8.4%7.4%8.0%
Net Margin % 1.3%1.3%1.4%1.3%1.2%1.2%0.7%1.1%1.1%0.8%-4.6%-0.7%0.4%-0.2%-1.6%-13.5%-39.8%
ROE % 13.5%13.6%12.9%12.5%11.2%10.8%6.7%10.4%11.3%7.2%-84.3%-13.5%4.2%-2.4%-4.5%-61.9%238.8%
ROCE % -19.2%17.4%16.8%15.3%14.9%9.0%11.7%11.9%4.3%-15.3%3.3%10.3%-7.2%6.7%7.1%14.7%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for ACH

Yahoo Finance Sun, 12 Jul 2026

Accendra Health (ACH) is One of The 15 Best NYSE Penny Stocks According to Hedge Funds

Accendra Health Inc. (NYSE:ACH) is one of the 15 best NYSE penny stocks to buy according to hedge funds. On June 23, Accendra Health Inc. (NYSE:ACH) disclosed the final settlement of its previously disclosed offer, involving its outstanding…

Yahoo Finance hu, 02 Jul 2026

Is the Options Market Predicting a Spike in Accendra Health Stock?

Investors need to pay close attention to ACH stock based on the movements in the options market lately.

Yahoo Finance Wed, 24 Jun 2026

Alchemy Pay Adds Illinois License as U.S. Regulatory Coverage Reaches 18 States

Alchemy Pay (CRYPTO: $ACH) has added Illinois to its U.S. regulatory map, giving the fiat-crypto payments company a...

Yahoo Finance Wed, 24 Jun 2026

Accendra Health Announces Expiration and Final Results of Offers and Consent Solicitations

RICHMOND, Va., June 24, 2026--Accendra Health, Inc. (NYSE: ACH) (the "Company") today announced the expiration and final results of the previously announced offers to exchange (the "Exchange Offers") any and all of the Company’s outstanding…

Yahoo Finance Wed, 10 Jun 2026

Accendra Health Announces Early Results of Exchange Offers

Accendra Health (ACH) said Wednesday that holders of nearly all of its outstanding 4.5% senior notes

Yahoo Finance Wed, 10 Jun 2026

Accendra Health Announces Early Results of Offers and Consent Solicitations

RICHMOND, Va., June 10, 2026--Accendra Health, Inc. (NYSE: ACH) (the "Company") today announced the early results of the previously announced offers to exchange (the "Exchange Offers") any and all of the Company’s outstanding 4.500% Senior …

ACH — Frequently Asked Questions

What is the current share price of Accendra Health, Inc. (ACH)?

As of 2026-07-15 16:51 PDT, Accendra Health, Inc. (ACH) trades at $3.63 on NYSE. Its 52-week range is $1.91 to $8.24.

What is the market capitalisation of ACH?

Accendra Health, Inc. (ACH) has a market capitalisation of $278.00M on NYSE.

What is the P/E ratio of ACH?

ACH trades at a trailing price-to-earnings (P/E) ratio of -2.65. The industry average P/E is 25.88. Its price-to-book (P/B) ratio is -0.55.

Is ACH a good stock to buy?

This page provides a data-driven analysis of Accendra Health, Inc. (ACH), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space